The economic burden of late entry into medical care for patients with HIV infection

John A. Fleishman, Baligh R. Yehia, Richard D Moore, Kelly Gebo

Research output: Contribution to journalArticle

Abstract

Context: A large proportion of people with human immunodeficiency virus (HIV) infection enter care late in the HIV disease course. Late entry can increase expenditures for care. Objective: To estimate direct medical care expenditures for HIV patients as a function of disease status at initial presentation to care. Late entry is defined as initial CD4 test result ≤200 cells/mm3, intermediate entry as initial CD4 counts >200, and ≤500 cells/mm3; and early entry as initial CD4 count >500. Patients: The study included 8348 patients who received HIV primary care and who were newly enrolled between 2000 and 2006 at one of 10 HIV clinics participating in the HIV Research Network. Design: We reviewed medical record data from 2000 to 2007. We estimated costs per outpatient visit and inpatient day, and monthly medication costs (antiretroviral and opportunistic illness prophylaxis). We multiplied unit costs by utilization measures to estimate expenditures for inpatient days, outpatient visits, HIV medications, and laboratory tests. We analyzed the association between cumulative expenditures and initial CD4 count, stratified by years in care. Results: Late entrants comprised 43.1% of new patients. The number of years receiving care after enrollment did not differ significantly across initial CD4 groups. Mean cumulative treatment expenditures ranged from $27,275 to $61,615 higher for late than early presenters. After 7 to 8 years in care, the difference was still substantial. Conclusions: Patients who enter medical care late in their HIV disease have substantially higher direct medical treatment expenditures than those who enter at earlier stages. Successful efforts to link patients with medical care earlier in the disease course may yield cost savings.

Original languageEnglish (US)
Pages (from-to)1071-1079
Number of pages9
JournalMedical Care
Volume48
Issue number12
DOIs
StatePublished - Dec 2010

Fingerprint

Virus Diseases
Patient Care
Health Expenditures
Economics
HIV
CD4 Lymphocyte Count
Costs and Cost Analysis
Inpatients
Outpatients
Cost Savings
Medical Records
Primary Health Care
Therapeutics
Research

Keywords

  • AIDS
  • expenditures
  • HIV
  • late presentation

ASJC Scopus subject areas

  • Public Health, Environmental and Occupational Health

Cite this

The economic burden of late entry into medical care for patients with HIV infection. / Fleishman, John A.; Yehia, Baligh R.; Moore, Richard D; Gebo, Kelly.

In: Medical Care, Vol. 48, No. 12, 12.2010, p. 1071-1079.

Research output: Contribution to journalArticle

Fleishman, John A. ; Yehia, Baligh R. ; Moore, Richard D ; Gebo, Kelly. / The economic burden of late entry into medical care for patients with HIV infection. In: Medical Care. 2010 ; Vol. 48, No. 12. pp. 1071-1079.
@article{1c10e4bdba234079bce3a6475076a590,
title = "The economic burden of late entry into medical care for patients with HIV infection",
abstract = "Context: A large proportion of people with human immunodeficiency virus (HIV) infection enter care late in the HIV disease course. Late entry can increase expenditures for care. Objective: To estimate direct medical care expenditures for HIV patients as a function of disease status at initial presentation to care. Late entry is defined as initial CD4 test result ≤200 cells/mm3, intermediate entry as initial CD4 counts >200, and ≤500 cells/mm3; and early entry as initial CD4 count >500. Patients: The study included 8348 patients who received HIV primary care and who were newly enrolled between 2000 and 2006 at one of 10 HIV clinics participating in the HIV Research Network. Design: We reviewed medical record data from 2000 to 2007. We estimated costs per outpatient visit and inpatient day, and monthly medication costs (antiretroviral and opportunistic illness prophylaxis). We multiplied unit costs by utilization measures to estimate expenditures for inpatient days, outpatient visits, HIV medications, and laboratory tests. We analyzed the association between cumulative expenditures and initial CD4 count, stratified by years in care. Results: Late entrants comprised 43.1{\%} of new patients. The number of years receiving care after enrollment did not differ significantly across initial CD4 groups. Mean cumulative treatment expenditures ranged from $27,275 to $61,615 higher for late than early presenters. After 7 to 8 years in care, the difference was still substantial. Conclusions: Patients who enter medical care late in their HIV disease have substantially higher direct medical treatment expenditures than those who enter at earlier stages. Successful efforts to link patients with medical care earlier in the disease course may yield cost savings.",
keywords = "AIDS, expenditures, HIV, late presentation",
author = "Fleishman, {John A.} and Yehia, {Baligh R.} and Moore, {Richard D} and Kelly Gebo",
year = "2010",
month = "12",
doi = "10.1097/MLR.0b013e3181f81c4a",
language = "English (US)",
volume = "48",
pages = "1071--1079",
journal = "Medical Care",
issn = "0025-7079",
publisher = "Lippincott Williams and Wilkins",
number = "12",

}

TY - JOUR

T1 - The economic burden of late entry into medical care for patients with HIV infection

AU - Fleishman, John A.

AU - Yehia, Baligh R.

AU - Moore, Richard D

AU - Gebo, Kelly

PY - 2010/12

Y1 - 2010/12

N2 - Context: A large proportion of people with human immunodeficiency virus (HIV) infection enter care late in the HIV disease course. Late entry can increase expenditures for care. Objective: To estimate direct medical care expenditures for HIV patients as a function of disease status at initial presentation to care. Late entry is defined as initial CD4 test result ≤200 cells/mm3, intermediate entry as initial CD4 counts >200, and ≤500 cells/mm3; and early entry as initial CD4 count >500. Patients: The study included 8348 patients who received HIV primary care and who were newly enrolled between 2000 and 2006 at one of 10 HIV clinics participating in the HIV Research Network. Design: We reviewed medical record data from 2000 to 2007. We estimated costs per outpatient visit and inpatient day, and monthly medication costs (antiretroviral and opportunistic illness prophylaxis). We multiplied unit costs by utilization measures to estimate expenditures for inpatient days, outpatient visits, HIV medications, and laboratory tests. We analyzed the association between cumulative expenditures and initial CD4 count, stratified by years in care. Results: Late entrants comprised 43.1% of new patients. The number of years receiving care after enrollment did not differ significantly across initial CD4 groups. Mean cumulative treatment expenditures ranged from $27,275 to $61,615 higher for late than early presenters. After 7 to 8 years in care, the difference was still substantial. Conclusions: Patients who enter medical care late in their HIV disease have substantially higher direct medical treatment expenditures than those who enter at earlier stages. Successful efforts to link patients with medical care earlier in the disease course may yield cost savings.

AB - Context: A large proportion of people with human immunodeficiency virus (HIV) infection enter care late in the HIV disease course. Late entry can increase expenditures for care. Objective: To estimate direct medical care expenditures for HIV patients as a function of disease status at initial presentation to care. Late entry is defined as initial CD4 test result ≤200 cells/mm3, intermediate entry as initial CD4 counts >200, and ≤500 cells/mm3; and early entry as initial CD4 count >500. Patients: The study included 8348 patients who received HIV primary care and who were newly enrolled between 2000 and 2006 at one of 10 HIV clinics participating in the HIV Research Network. Design: We reviewed medical record data from 2000 to 2007. We estimated costs per outpatient visit and inpatient day, and monthly medication costs (antiretroviral and opportunistic illness prophylaxis). We multiplied unit costs by utilization measures to estimate expenditures for inpatient days, outpatient visits, HIV medications, and laboratory tests. We analyzed the association between cumulative expenditures and initial CD4 count, stratified by years in care. Results: Late entrants comprised 43.1% of new patients. The number of years receiving care after enrollment did not differ significantly across initial CD4 groups. Mean cumulative treatment expenditures ranged from $27,275 to $61,615 higher for late than early presenters. After 7 to 8 years in care, the difference was still substantial. Conclusions: Patients who enter medical care late in their HIV disease have substantially higher direct medical treatment expenditures than those who enter at earlier stages. Successful efforts to link patients with medical care earlier in the disease course may yield cost savings.

KW - AIDS

KW - expenditures

KW - HIV

KW - late presentation

UR - http://www.scopus.com/inward/record.url?scp=78650174026&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=78650174026&partnerID=8YFLogxK

U2 - 10.1097/MLR.0b013e3181f81c4a

DO - 10.1097/MLR.0b013e3181f81c4a

M3 - Article

C2 - 21063228

AN - SCOPUS:78650174026

VL - 48

SP - 1071

EP - 1079

JO - Medical Care

JF - Medical Care

SN - 0025-7079

IS - 12

ER -